Your browser version may not work well with NCBI's Web applications. More information here...
1: Cancer Invest. 2008 Mar;26(2):208-16.Click here to read Links

Treatment strategies in myelodysplastic syndromes.

Atallah E, Garcia-Manero G.

Department of Neoplastic Diseases, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Myelodysplastic syndromes (MDS) are a group of disorders characterized by progressive cytopenias and transformation to acute leukemia. Over the last four years, we have experienced a revolution in the treatment of MDS. Three drugs were approved in the U.S. Two of them, 5-azacitidine and 5-aza-2'-deoxycitidine, induce DNA hypomethylation. The third agent, lenalidomide, is a thalidomide analogue with significant activity in a subset of patients with low-risk MDS, anemia and chromosome 5 alterations. Several other agents are being evaluated in MDS. In this short review, we will summarize our current approach to the therapy of patients with MDS.

PMID: 18259954 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Thalidomide (Thalomid® )

    Thalidomide is used along with dexamethasone to treat multiple myeloma in people who have been recently found to have this disease. It is also used alone or with other medications to treat and prevent skin symptoms of er...

  • Lenalidomide (Revlimid® )

    Lenalidomide is used to treat a certain type of myelodysplastic syndrome (a group of conditions in which the bone marrow produces blood cells that are misshapen and does not produce enough healthy blood cells). Lenalidom...

  • Source: AHFS Consumer Medication Information